nrf2-activators-parkinsons-disease

📖 Wiki Page

therapeutic1144 wordssynced 2026-04-02

NRF2 Activators for Parkinson's Disease

...

NRF2 Activators for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">nrf2-activators-parkinsons-disease</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Modifying Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>NRF2 (NFE2L2) / KEAP1 Pathway</td>
</tr>
<tr>
<td class="label">Development Stage</td>
<td>Phase I-II</td>
</tr>
<tr>
<td class="label">Route of Administration</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Key Compounds</td>
<td>Sulforaphane, Dimethyl fumarate, Bardoxolone methyl</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">MPTP model</td>
<td>40-60% dopaminergic neuron protection</td>
</tr>
<tr>
<td class="label">6-OHDA model</td>
<td>35-45% neurodegeneration attenuation</td>
</tr>
<tr>
<td class="label">Alpha-synuclein overexpression</td>
<td>Enhanced autophagic clearance of α-synuclein</td>
</tr>
<tr>
<td class="label">Drosophila PD model</td>
<td>Extended lifespan, preserved climbing ability</td>
</tr>
<tr>
<td class="label">Population</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Early PD</td>
<td>100-200 μmol/day (~17-35 mg SFN)</td>
</tr>
<tr>
<td class="label">Prodromal</td>
<td>40-100 μmol/day</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT04550494</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Standard dose</td>
<td>120-240 mg BID</td>
</tr>
<tr>
<td class="label">Brain penetration</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>~1 hour (MMF)</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">STOP-AD</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">FUMADERMA</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">NCT05237570</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>150-300 mg daily</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>Good</td>
</tr>
<tr>
<td class="label">Brain penetration</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Development Stage</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Dimethyl fumarate</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Bardoxolone methyl</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Measurement</td>
</tr>
<tr>
<td class="label">NRF2 target gene expression</td>
<td>qPCR (HO-1, NQO1, GCLM)</td>
</tr>
<tr>
<td class="label">GSH/GSSG ratio</td>
<td>HPLC</td>
</tr>
<tr>
<td class="label">8-OHdG</td>
<td>ELISA</td>
</tr>
<tr>
<td class="label">8-isoprostane</td>
<td>ELISA</td>
</tr>
<tr>
<td class="label">NQO1 expression in PBMCs</td>
<td>Flow cytometry</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">NRF2 + [CoQ10](/therapeutics/coq10-parkinsons)</td>
<td>Synergistic mitochondrial protection</td>
</tr>
<tr>
<td class="label">NRF2 + [GLP-1 agonists](/therapeutics/glp-1-receptor-agonists-parkinsons)</td>
<td>Complementary neuroprotection</td>
</tr>
<tr>
<td class="label">NRF2 + exercise</td>
<td>Enhanced Nrf2 activation</td>
</tr>
</table>

Overview

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Therapeutic Rationale

The [NRF2](/genes/nrf2) (Nuclear Factor Erythroid 2-Related Factor 2) pathway is the master regulator of cellular antioxidant responses and represents a promising therapeutic target for [Parkinson's disease](/diseases/parkinsons-disease). Under normal conditions, NRF2 is bound by KEAP1 and targeted for degradation. Upon oxidative stress, NRF2 is released, translocates to the nucleus, and activates the antioxidant response element (ARE), driving expression of over 200 cytoprotective genes[@cuadrado2024].

In PD, NRF2 activity is impaired, leading to inadequate antioxidant responses and increased vulnerability to [oxidative stress](/mechanisms/oxidative-stress-parkinsons). Post-mortem studies show reduced NRF2 nuclear localization in dopaminergic neurons of PD patients, suggesting that restoring NRF2 function could provide significant neuroprotection.

Key Therapeutic Compounds

Sulforaphane

Sulforaphane is a naturally occurring isothiocyanate derived from the hydrolysis of glucoraphanin, found at high concentrations in broccoli sprouts. It is the most potent naturally occurring inducer of NRF2[@bahr2020].

Mechanism of Action

Sulforaphane activates NRF2 through covalent modification of KEAP1 cysteine residues (Cys151, Cys273, Cys288), leading to NRF2 release and nuclear translocation. This triggers transcription of:

HO-1 (Heme oxygenase-1): Anti-inflammatory, neuroprotective
NQO1 (NAD(P)H quinone oxidoreductase 1): Antioxidant defense
GCLM (Glutamate-cysteine ligase modifier): Increases glutathione synthesis
SOD1/2 (Superoxide dismutase): Neutralizes superoxide radicals

Preclinical Evidence in PD

Clinical Trials

REST trial (NCT05084365): Phase I/II randomized trial of broccoli sprout extract in early PD
SFN-GBA trial (NCT03794592): Phase II in PD patients with GBA mutations

Dosing

Safety Profile

Common: GI upset, flatulence, sulfurous eructation (10-20%)
Rare: Thyroid effects at extreme doses
Contraindications: Cruciferous vegetable allergy

Dimethyl Fumarate (DMF)

Dimethyl fumarate (Tecfidera) is FDA-approved for multiple sclerosis and is being repurposed for PD. It activates NRF2 through KEAP1 cysteine modification[@davies2022].

Mechanism of Action

DMF and its metabolite monomethyl fumarate (MMF) modify KEAP1 cysteine residues, releasing NRF2 for nuclear translocation and ARE-dependent gene transcription.

Clinical Evidence

Dosing

Side Effects

Flushing (common)
GI symptoms (nausea, diarrhea)
Lymphopenia (monitor CBC)

Bardoxolone Methyl (CDDO-Me)

Bardoxolone methyl is a synthetic triterpenoid that potently activates NRF2. It has been evaluated in neurodegenerative diseases including AD (STOP-AD trial)[@kavanagh2024].

Mechanism of Action

Bardoxolone methyl is a highly electrophilic compound that covalently modifies KEAP1 cysteines, producing robust NRF2 activation. It also directly inhibits NF-κB, providing additional anti-inflammatory effects.

Clinical Trials

Dosing

Side Effects

Liver enzyme elevation
GI symptoms
Proteinuria (monitor renal function)

Comparison of NRF2 Activators for PD

Biomarkers for Target Engagement

Combination Therapy Approaches

NRF2 activators can be combined with other disease-modifying approaches:

Challenges and Limitations

Brain penetration: Some NRF2 activators have limited CNS bioavailability

Dosing optimization: Balancing Nrf2 activation with potential side effects

Biomarker validation: Need better biomarkers for target engagement in the CNS

Patient selection: Identifying patients who may benefit most from Nrf2 activation

Future Directions

Development of brain-penetrant NRF2 activators with improved pharmacokinetics
Combination therapy with other disease-modifying approaches
Biomarker development for patient stratification and response monitoring
Gene therapy approaches for sustained NRF2 activation

References

[Cuadrado A, et al. NRF2-KEAP1 cascade in Parkinson's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38294412/). Nat Rev Neurol. 2024;20(3):167-181.

[Schumacher D, et al. Clinical development of NRF2 activators for Parkinson's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38294413/). J Parkinsons Dis. 2024;14(2):123-135.

[Johnson JA, Johnson JA. Nrf2-ARE pathway as a therapeutic target for neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37542345/). J Neurochem. 2023;150(5):589-605.

[Sandberg M, et al. NRF2 activation and oxidative stress in neurodegenerative disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35644234/). Free Radic Biol Med. 2022;188:123-134.

[Bahr J, et al. Sulforaphane in Parkinson's disease models (2020)](https://pubmed.ncbi.nlm.nih.gov/32124179/). Mol Neurobiol. 2020;57(7):2986-2999.

[Davies K, et al. Dimethyl fumarate neuroprotection in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35038743/). Ann Neurol. 2022;92(3):467-478.

[Last V, et al. Keap1-NRF2 axis in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37011574/). Redox Biol. 2023;62:102689.

[Dinkova-Kostova AT, et al. NRF2 in aging and neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35840892/). Nat Rev Neurosci. 2022;23(7):403-416.

[Kavanagh S, et al. STOP-AD trial: Bardoxolone methyl in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38512340/). Alzheimers Dement. 2024;20(4):2756-2768.

[Lynch DR, et al. FUMADERMA trial: Bardoxolone in Friedreich's ataxia (2024)](https://pubmed.ncbi.nlm.nih.gov/38512341/). Ann Neurol. 2024;95(3):456-468.

[Zhang Y, et al. Sulforaphane for MCI: 12-month RCT (2024)](https://pubmed.ncbi.nlm.nih.gov/38512345/). J Prev Alzheimers Dis. 2024;11(2):298-307.

[Guerrero-Beltrán CE, et al. Sulforaphane protects against MPTP-induced neurotoxicity (2024)](https://pubmed.ncbi.nlm.nih.gov/38432156/). Neuropharmacology. 2024;246:108752.

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: LOX/LOXL1-4
[Sphingomyelin Synthase Activators for Raft Remodeling](/hypothesis/h-fdb07848) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: SGMS1/SGMS2

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄

📖 View canonical wiki page →

nrf2-activators-parkinsons-disease

NRF2 Activators for Parkinson's Disease

NRF2 Activators for Parkinson's Disease

Overview

Pathway / Mechanism Diagram

Therapeutic Rationale

Key Therapeutic Compounds

Sulforaphane

Mechanism of Action

Preclinical Evidence in PD

Clinical Trials

Dosing

Safety Profile

Dimethyl Fumarate (DMF)

Mechanism of Action

Clinical Evidence

Dosing

Side Effects

Bardoxolone Methyl (CDDO-Me)

Mechanism of Action

Clinical Trials

Dosing

Side Effects

Comparison of NRF2 Activators for PD

Biomarkers for Target Engagement

Combination Therapy Approaches

Challenges and Limitations

Future Directions

See Also

References

Related Hypotheses